linjc16/ctgov huggingface dataset:
Study of Botulinum Toxin in Patients With Primary Hyperhidrosis

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Determine the optimal dose of botulinum toxin necessary to decrease sweating in patients with primary hyperhidrosis.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients receive injections of botulinum toxin in the clinical trial for 6 months. Patients undergo an iodine starch test and a sympathetic skin response test to assess the efficacy of the drug. Patients also complete questionnaires to evaluate the amount of sweating.

Conditions
-----------------
Hyperhidrosis

Intervention / Treatment
-----------------
* Drug: botulinum toxin type A


Participation Criteria
=================
Eligibility Criteria
-----------------
Diagnosis of hyperhidrosis Excessive sweating in the hands, feet, armpits, forehead, or body

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: botulinum toxin type A|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dermatologic disorders, hyperhidrosis, rare disease
Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)

Study Overview
=================
Brief Summary
-----------------
Cerebral and medullary arteriovenous malformations (AVMs) are morphologically abnormal vessels located on the surface or in the cerebral or medullary parenchyma. These vascular lesions cause the arterial and venous networks to communicate pathologically, creating an arteriovenous shunt.The prevalence of cerebral Cerebral and medullary AVMs in general population is difficult to establish given the rarity of the condition. However, it is estimated at around 1 per 10,000 inhabitants (0.01%). About 15-20% of the cerebral vascular accidents are asymptomatic at the time of diagnosis. The occurrence of intracranial haemorrhage is the most important prognostic factor because it is associated with a significant morbidity and mortality. The management of an AVM is usually carried out in a multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular neurology. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known. Several recent research works highlight mutations in the RAS-MAPK or MAPK-ERK signalling pathway in AVMs. In cases of cerebral AVMs considered to be sporadic, a somatic KRAS/BRAF mutation has recently been demonstrated in tissue samples of operated AVMs. Except in the case of Hereditary Haemorrhagic Telangiectasia (HHT or Rendu-Osler-Weber syndrome), the influence of genetic damage on the prognosis of AVM is poorly known. It is also interesting to note that genetic screening is not routinely performed in patients with cerebro-medullary AVMs and that therefore the prevalence of these clinical entities in patients with AVMs is not known.

Official Title
-----------------
Genetics of Central Nervous System Arteriovenous Malformations (AVM): Genotype-Phenotype Correlation and Prognostic Impact on Patients With AVM

Conditions
-----------------
Arteriovenous Malformations

Intervention / Treatment
-----------------
* Genetic: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research. Exclusion Criteria: Pregnant, parturient or breastfeeding woman
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: blood sample|During the arteriography a peripheral venous sampling|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic mutation |  | limit of 12 month |
Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure

Study Overview
=================
Brief Summary
-----------------
Women with history of previous IVF cycle failure will be subjected to a fresh IVF cycle. At the time they will be undergoing embryo transfer, 50 IU of human chorionic gonadotropins diluted in 0.025ml of tissue culture media will be injected intrauterine by embryo transfer catheter 10 minutes before embryo transfer procedure.

Detailed Description
-----------------
Infertile women with history of previous IVF cycle failure will be subjected top a fresh IVF cycle. Following controlled ovarian hyperstimulation, ovum pick up and at the time they will be undergoing embryo transfer, 50 IU of human chorionic gonadotropins diluted in 0.025ml of tissue culture media will be injected intrauterine by embryo transfer catheter 10 minutes before embryo transfer procedure.

Conditions
-----------------
Infertility, Invitro Fertilization

Intervention / Treatment
-----------------
* Drug: Human Chorionic Gonadotropin (HCG)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - women with previous IVF failure undergoing fresh IVF cycle Exclusion Criteria: women with hydrosalpinges women with intrauterine lesion like submucous fibroid or polyps

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure. | Drug: Human Chorionic Gonadotropin (HCG)<br>* intrauterine injection of HCG prior to embryo transfer in an IVF cycle<br>* Other names: u-hCG;|
| No Intervention: Group B<br>women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Live Birth |  | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility, Invitro fertilization
An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

Study Overview
=================
Brief Summary
-----------------
To characterize the pharmacokinetics of orally administered FLT (in a liquid formulation) after single doses in both the fed and fasting states; to assess the effect of food on the oral bioavailability of FLT

Official Title
-----------------
An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Alovudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Positive ELISA test confirmed by Western blot analysis. Asymptomatic. Willing to sign an informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. Oral hairy leukoplakia at any time prior to entry. Temperature > 37.8 C. Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. Significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. Unwilling to sign an informed consent. Zidovudine induced hematological toxicity. Prior Medication: Excluded: Therapy with antiretroviral drugs or immunomodulators within seven days before entry. Therapy with any investigational drug during the preceding 30 days. Patients may not have: Oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. Oral hairy leukoplakia at any time prior to entry. Temperature > 37.8 C. Any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. Significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. Unwilling to sign an informed consent. Zidovudine induced hematological toxicity.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Alovudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biological Availability, alovudine, Food
The Effectiveness of Pasteurized Goat Milk in the Treatment of Childhood Oral Ulcer Diseases

Study Overview
=================
Brief Summary
-----------------
Children with acute diseases with oral ulcers (not included PRESENTATIONS OF SLE, IBD or IMMUNOCOMPRMIZED STATES)will receive several doses (drinking or mouth rinsing) of either pasteurized goat milk or cow milk. Children will than be followed for length of the disease - signs and symptoms.

Detailed Description
-----------------
A prospective randomized controlled study that will include 110 previously health 6months - 5 years children (55 in each group) with acute oral ulcer disease (< 48 hours). Children will receive several doses (drinking or mouth rinsing) of either pasteurized goat milk or cow milk. Children will than be followed for length of the disease - sings and symptoms by questioner to parents, and physical examination by there physicians. .

Official Title
-----------------
Phase 1 1 Study Assesing the Benefit of Pasteurized Goat Milk in Reducing Disease Severity of Young Children With Oral Ulcer Diseases

Conditions
-----------------
Oral Ulcer

Intervention / Treatment
-----------------
* Biological: Drinking or rinsing the mouth 2-3 times for 1 day
* Biological: Pasturlized cow milk


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 6 months or < 5 years. Acute (< 48 hours) oral ulcer disease. > 5 ulcers. Cooperative parents . Signing inform consent. Exclusion Criteria: All types of immunosuppression, IBD, SLE, recurrent oral ulcer, disease > 48 hours, age , 6 < months or > 5 years.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>55 children < 5 years with acute oral ulcer disease. | Biological: Drinking or rinsing the mouth 2-3 times for 1 day<br> <br> |
| Placebo Comparator: 2<br>55 Children < 5 years with acute oral ulcer disease. | Biological: Pasturlized cow milk<br>* Drinking or rinsing the mouth 2-3 times for one day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of disease |  | 3 years | 
| Length of disease |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
children
Effectiveness of Buddhist Intergrated Group Intervention on Minefulness in Adolescents

Study Overview
=================
Brief Summary
-----------------
The pupose of the study is to determine the effectiveness of the Buddhist integrated group intervention improve the mindfulness in adolescents by a randomized controlled trial.The study divede the adolescents in two groups group A recieved the 8 time Buddhist group interventions.Group recieved nothing.The measurement were done pre and post intervention at week1 and week8.The mindfulness score ,the EQ,the MASS score were compared between both groups.

Detailed Description
-----------------
Adolescence behavioural problems are increasing including learning disabilities,game addiction,intolerance etc.The improvement of mindfulness ,the emotional quotient(EQ) proved to be effective to reduce the problems.The original teaching methods in school or in the temple are inadequate from increasing number of adolescent problems. The new technique integrated between Buddhism and group intervention is proposed to improve the mindfulness and EQ in adolescence.

Official Title
-----------------
Department of Orthopedic Surgery, Faculty of Medicine Siriraj Hospital

Conditions
-----------------
Other Conditions That May Be A Focus of Clinical Attention

Intervention / Treatment
-----------------
* Behavioral: buddhist mind fullness


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adolescents Exclusion Criteria: incomplete qeustionaire and intervention

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: recieves Buddhist mindfullness<br> | Behavioral: buddhist mind fullness<br>* there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing<br>* Other names: no other name;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mindfulness score,The EQ score,the MASS score of the participants after intervention. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mindfulness EQ adolescents
Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters

Study Overview
=================
Brief Summary
-----------------
Regional tissue oxygenation (rStO2) can be monitored by near infrared spectroscopy. The commercial devices FORE-SIGHT (CASMED) and INVOS (COVIDIEN) will be used simultaneously to test for their relative sensitivity for low oxygen levels just after birth on term infants born by elective cesarean section. Reproducibility will be examined by replacements of the sensors six times the next day when the infant is stable and quiet. Neonatal sensors will be used.

Official Title
-----------------
Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters Absolute Values, Sensitivity for Low Oxygen Levels and Reproducibility..

Conditions
-----------------
Near Infrared Spectroscopy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Term infants (age more than 37 weeks of gestation) Elective cesarean section after an uncomplicated pregnancy Exclusion criteria: Thick hair that makes good measurements difficult/impossible Obvious malformations or syndrome Complications in relation to the cesarean section Depression after birth (APGAR < 8 after 1 minute)

Ages Eligible for Study
-----------------
Maximum Age: 2 Minutes

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral oxygenation | The sensors of both instruments will be placed on each side of the head. They will be held by hand or by self-adhesive tape as appropriate. Curve fitting will be used to describe the rapid increase of oxygenation after birth. Estimated cerebral oxygenation at 3 min (hypoxia) and 10 min (normoxia) will be used to compare the two instruments. | 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility | The sensor will be placed 6 times alternating on each frontoparietal region and held by hand, obtaining 30 seconds of signal for each placement. The placements will be in the same region but not in exactly the same spot. This will be done for both devices. | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Oximetry, Near infrared spectroscopy, Fullterm, Infant
Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

Detailed Description
-----------------
Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

Official Title
-----------------
Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease

Conditions
-----------------
Chronic Lung Diseases, COPD, Pulmonary Fibrosis

Intervention / Treatment
-----------------
* Other: Disclosure Writing (Written Disclosure Therapy)
* Other: Neutral (Sham) Writing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of COPD or Pulmonary Fibrosis First time participants in Pulmonary Rehabilitation program Exclusion Criteria: Dementia Prior significant psychiatric illness Inability to complete the questionnaires Inability cooperate with spirometry Inability or to participate in outpatient follow-up over the six-month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Written Disclosure Therapy<br> | Other: Disclosure Writing (Written Disclosure Therapy)<br>* Patients write about a stressful life experience<br>* Other names: Written Disclosure Therapy;|
| Sham Comparator: Controls<br> | Other: Neutral (Sham) Writing<br>* Patients write about neutral subjects<br>* Other names: Sham Writing (Controls that wrote about neutral subjects);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspnea and quality of life |  | Two-month and six-month time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Six-minute walk distance |  | Two-month and six-month time | 
| Spirometry values (FEV1 and FVC) |  | Two-month and six-month time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyspnea, Written Disclosure Therapy, COPD, Pulmonary Fibrosis, Chronic Lung Diseases, Pulmonary Rehabilitation